CoChat

Troglitazone Hepatotoxicity: Are We Getting Closer to Understanding Idiosyncratic Liver Injury?

Open access
Jaeschke, H. · 2007 · Toxicological Sciences
Cited by 55

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Idiosyncratic hepatotoxicity is a rare and unpredictable event of liver injury affecting generally less than 1 in 10,000 patients treated with certain drugs. However, it is a serious clinical problem as it accounts for 10% of all drug-induced liver failure cases (Kaplowitz, 2005). Since idiosyncratic drug reactions are not detected in preclinical testing and in most cases not even during clinical trials, the problem surfaces generally after the drug is approved and hundreds of thousands of patients are being treated. Idiosyncratic hepatotoxicities are currently the main cause for Food and Drug Administration-mandated warnings, restrictions of use or even withdrawals of drugs from the market (Kaplowitz, 2005). As such, this is a considerable problem for the pharmaceutical industry and for regulatory agencies worldwide. One of the recent examples of drugs causing idiosyncratic hepatotoxicity and liver failure was the antidiabetic drug Rezulin (troglitazone). Troglitazone, a peroxisome proliferator–activated receptor gamma agonist, which enhances insulin sensitivity, was approved for the treatment of type 2 diabetes in 1997. Troglitazone was an effective antidiabetic drug with a fundamentally new mechanism of action. However, within a year after its widespread use, individual cases of liver injury and failure were reported (Watkins, 2005). The mounting evidence for the idiosyncratic hepatotoxicity of troglitazone in the following years and the development of rosiglitazone and pioglitazone, drugs with a similar mechanism of action but presumably without the liver liabilities, led to the withdrawal of troglitazone from the market in the year 2000. Since then, a considerable effort has been made to elucidate the mechanism of troglitazone-induced hepatotoxicity. A number of hypotheses were brought forward to explain troglitazone-induced cell injury including the formation and accumulation of toxic metabolites, mitochondrial dysfunction and oxidant stress, inhibition of the bile salt transporter and bile acid toxicity, and the induction of apoptosis (Choijker, 2005). However, virtually all the studies were performed with cultured cell lines using concentrations of troglitazone 1–2 orders of magnitude above pharmacological levels. Thus, these in vitro studies could not provide a relevant mechanistic explanation for troglitazone hepatotoxicity in patients (Choijker, 2005). Nevertheless, some of these experiments demonstrated that high concentrations of troglitazone can induce mitochondrial dysfunction in these cell lines (Haskins et al., 2001; Tirmenstein et al., 2002). Furthermore, troglitazone, but not rosiglitazone or pioglitazone, was able to induce the mitochondrial membrane permeability transition pore opening in isolated rat liver mitochondria (Masubuchi et al., 2006). Although these mechanisms appear not to be relevant for damage in normal hepatocytes in vivo, it raises the possibility that under certain conditions troglitazone has the potential to cause a mitochondrial stress. The currently favored concept of idiosyncratic hepatotoxicity assumes that the injury is caused by a combination of certain genetic and environmental factors, which sufficiently enhance an individual's susceptibility to otherwise clinically silent adverse effects of a drug (Watkins, 2005). This may more likely develop into a problem when the cellular stress caused by the drug superimposes with the stress of the disease to be treated (Boelsterli, 2003). For example, obesity, diabetes, and steatosis result in a chronic oxidant stress and mitochondrial dysfunction (Pessayre et al., 2001), which may enhance the toxicity of drugs that target mitochondria, e.g., acetaminophen (Jaeschke and Bajt, 2006). In fact, acetaminophen hepatotoxicity is significantly aggravated in obese and diabetic mice (Kon et al., 2005). Mitochondrial dysfunction is generally accompanied by enhanced reactive oxygen formation. A critical defense against mitochondrial oxidant stress is the mitochondrial enzyme manganese superoxide dismutase (MnSOD, SOD2). SOD2-deficient mice (SOD2−/−) die within a few days after birth underscoring the critical importance of continuously detoxifying mitochondria-derived reactive oxygen species. However, mice partially deficient in SOD2 (SOD2+/−) are viable and initially without pathology. However, the lifelong reduction of mitochondrial SOD2 levels causes a gradual accumulation of mitochondrial and nuclear oxidative DNA damage, which results in a higher tumor rate compared to wild-type animals (VanRemmen et al., 2003). Thus, younger SOD2+/− mice can be considered a model of a chronic, subclinical mitochondrial stress. Based on these previous observations, Ong et al. (2007) hypothesized that animals with a genetic defect in the mitochondrial antioxidant defense mechanisms may be susceptible to chronic exposure of troglitazone. To test their hypothesis, the authors treated wild type and SOD2+/− mice with 10 or 30 mg/kg troglitazone (ip)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/toxsci/kfm021

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 55

Metadata

Authors
Jaeschke, H.
Venue
Toxicological Sciences
Published
2007-05-01
Volume
97
Issue
1
Pages
1-3
ISSN
  • 1096-0929 (ISSN-L)
  • 1096-6080
OpenAlex
W1991214197
Cited by
55
References
2
FWCI
3.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Troglitazone Hepatotoxicity: Are We Getting Closer to Understanding Idiosyncratic Liver Injury? https://app.cochat.ai/papers/10.1093/toxsci/kfm021
The paper
Jaeschke, H. (2007). Troglitazone Hepatotoxicity: Are We Getting Closer to Understanding Idiosyncratic Liver Injury? Toxicological Sciences. https://doi.org/10.1093/toxsci/kfm021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.